Saturday, 31 October 2026European Markets

BELSHIPS Stock Bullish Momentum With A 9.38% Jump On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with BELSHIPS (BELCO.OL) jumping 9.38% to kr21.05 on Tuesday, after two consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI slid 0% to kr1,412.36, following the last session's upward trend on what was a somewhat positive trend exchanging session today.

BELSHIPS's last close was kr19.24, 13.53% below its 52-week high of kr22.25.

About BELSHIPS

Belships ASA owns and operates dry bulk ships worldwide. It operates through Belships and Lighthouse Navigation segments. The company operates a fleet of 38 modern Supra/Ultramax bulk carriers, including newbuildings. It also provides technical, crewing, port agency, and logistical services. The company was founded in 1918 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, BELSHIPS has a trailing twelve months EPS of kr2.45.

PE Ratio

BELSHIPS has a trailing twelve months price to earnings ratio of 8.59. Meaning, the purchaser of the share is investing kr8.59 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 50.41%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 50.8%, now sitting on 614.13M for the twelve trailing months.

Moving Average

BELSHIPS's worth is way higher than its 50-day moving average of kr17.17 and way above its 200-day moving average of kr17.20.

More news about BELSHIPS (BELCO.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
BELSHIPS Stock Bullish Momentum With A 9.38% Jump On Tuesday | ViaNews EU